嵌合抗原受体T细胞（CAR-T）和新型靶向治疗等生物免疫疗法的临床应用开辟了多发性骨髓瘤（MM）治疗的新领域。靶向B细胞成熟抗原（BCMA）、同种异体CAR-T、抗体偶联药物（ADC）及靶向BCMA的双特异性抗体在多项临床研究中获得了令人瞩目的疗效及较好的安全性。文章结合第62届美国血液学会（ASH）年会的相关报道对MM免疫治疗进展进行介绍。“,”The clinical application of biological immunotherapy such as chimeric antigen receptor T cells (CAR-T) and novel targeted therapy has explored a new therapy for multiple myeloma (MM) treatment. Targeting B-cell maturation antigen (BCMA), allogeneic CAR-T, antibody-drug conjugate (ADC) and bispecific antibody targeting BCMA have achieved remarkable efficacy and safety in many clinical studies. This article introduces the latest immunotherapy for MM at the 62nd American Society of Hematology (ASH) Annual Meeting.